Summit Therapeutics plc
(‘the Company’)
Total voting rights
Oxford, UK, and Cambridge, MA, US 3 September 2018 – Summit Therapeutics plc (AIM:SUMM, NASDAQ:SMMT), announces that in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital as at the close of business on 31 August 2018 consisted of 82,125,995 ordinary shares of 1 pence each (‘Ordinary Shares’). There are no Ordinary Shares held in treasury.
Accordingly, the total number of voting rights in Summit Therapeutics plc at the date of this notice is 82,125,995.
The above figure of 82,125,995 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
-END-
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit | ||
| Glyn Edwards / Richard Pye (UK office) | Tel: | 44 (0)1235 443 951 |
| Erik Ostrowski / Michelle Avery (US office) | +1 617 225 4455 | |
| Cairn Financial Advisers LLP (Nominated Adviser) | Tel: | +44 (0)20 7213 0880 |
| Liam Murray / Tony Rawlinson |